Post Reply
8461-8480 of 10899
alamak.. tat guy really think it will shoot up tat fast.. no lah.. i reckon de first px will hit 1.08 during opening.. but 1.5...haha.. i tink he just place order for fun oni lah.. when he/she see lifting announced.. he will cancel de order and place another px.. heehee..
cashiertan.. how.. got secure? really hope u do.. cos u have been helpin others by given relevant info.. we all wish u and de rest of us HUAT too..
This one more clearer.. Why so big spread?? Does this means that when halt lifted the price will shoot up to $1.5??
| Symbol | Last | Description | Mkt | Chg | % Chg | Bid | Ask | Vol | High | Low | Open | Remark | Bid Size | Ask Size | Tools | ||||||
 |
|||||||||||||||||||||
| Buy | Sell | B20 | SGD | 1.040 | BIOSENSORS | SG | 0.000 | 0.000 | 1.500 | 1.020 | 0 | 0.000 | 0.000 | 0.000 | H | 10,000 | 155,000 |  |
 |
||
Hey~!
According to my DBSvickers trading system, someone is bidding at $1.5 but the asking price is $1.02???? how come so big different??
| Symbol | Last | Description | Mkt | Chg | % Chg | Bid | Ask | Vol | High | Low | Open | Remark | Bid Size | Ask Size | Tools | |||||
| Buy | Sell | B20 | SGD | 1.040 | BIOSENSORS | SG | 0.000 | 0.000 | 1.500 | 1.020 | 0 | 0.000 | 0.000 | 0.000 | H | 10,000 | 155,000 | |
|
Cheers!!! All bios supporters.... That's the way, Ah Ha!! Ah Ha!! I like it!!!
Thanks!! Bengster for your hardwork!!!
Now the katek die PAIN PAIN!!!
NEWS RELEASE
Biosensors Receives CE Mark Approval for its BioMatrix®
Drug-Eluting Coronary Stent System
Singapore, 18 January 2008 ?
?Company? or ?Biosensors?), today announced that the Company has received
Conformite Europeenne (?CE?) Mark approval for its BioMatrix® drug-eluting stent
system, enabling commercialization of this product in the European Union and the
countries in Asia and Latin America that recognize the CE Mark. The BioMatrix drugeluting
stent system, developed internally by the Company, consists of a unique drugeluting
stent that incorporates a biodegradable polymer and the Company?s proprietary
drug, Biolimus A9®, which inhibits restenosis, or re-narrowing of the arteries, following
stent implantation.
Terumo Corporation (?Terumo?), a licensee of Biosensors? BioMatrix technology, also
announced CE Mark approval for its NOBORI? drug-eluting stent system. In October
2003, Biosensors and Terumo entered into a licensing agreement that granted Terumo
the rights to sell the NOBORI drug-eluting stent system exclusively in Japan and nonexclusively
in countries outside Japan excluding the United States. Under this
agreement, Terumo will share a portion of the revenues from the sales of NOBORI with
Biosensors. In May 2007, Terumo commenced the clinical trial of the NOBORI drugeluting
stent system required for Japanese regulatory approvals.
?We are very pleased to have received CE Mark approval for our BioMatrix stent and
will immediately implement our strategy to make this product available in the approved
markets. Our growth potential in these markets is very strong, as BioMatrix and NOBORI
will be the only drug-eluting stents currently available which incorporate a
biodegradable polymer coating together with an immunosuppressive drug. Positive
clinical data position the BioMatrix stent system to be a potential break-through
product for patients and physicians,? stated Mr. Yoh-Chie Lu, Chairman and Chief
Executive Officer.
Professor Eberhard Grube, Chief of Angiology and Cardiology at Siegburg Heart Center in
Germany and a principal investigator for the BioMatrix clinical trial program
commented, ?BioMatrix will provide a valuable alternative to the drug-eluting stents
currently available to interventional cardiologists. The results from the BioMatrix clinical
trials have been consistently very positive and promising. The three-year follow-up data
released at the Transcatheter Cardiovascular Therapeutics Conference last year
continued to demonstrate BioMatrix?s superior results in terms of safety and clinical
effectiveness. The BioMatrix drug eluting stent has shown excellent procedural
performance and outcome characteristics.?
Mr. Lu added, ?We are also pleased with the timing of this approval, as the increasing
complexity of worldwide regulatory requirements will make it even more difficult to
introduce new technologies into the marketplace. We plan to commence a staged
launch of BioMatrix commencing 1 April 2008. The initial stage will be to introduce
BioMatrix through our existing distribution channels. We will expand these channels to
increase geographical coverage during the first half of our fiscal year beginning in April,
2008 and plan a significant ramp up in sales over the second half of our fiscal year.?
?Many years of effort devoted to developing the BioMatrix drug-eluting stent system
have been validated by this approval. We would like to take this opportunity to
recognize the contributions of our people and the collaborative efforts of our licensees,
especially Terumo Corporation, in achieving this milestone. This is truly an historic day
for Biosensors,? concluded Mr. Lu
Biosensors International Group, Ltd. (Bloomberg: BIG SP,## End of Release ##
Media & Investor Relations
Singapore
Mr. Loh Chee Mun
Senior Vice President
Tel: (65) 62135708
Email:
cm.loh@biosensors.comUnited States
Allen&Caron Inc.
Mr. Matt Clawson
Executive Vice President, Investor Relations
Tel: (1) 949 474 4300
Email:
matt@allencaron.comAbout BioMatrix
BioMatrix offers the unique combination of an innovative anti-restenosic drug, Biolimus
A9
Biolimus A9 was designed specifically to maximize stent efficacy. In addition to effective
immunosuppressive and anti-inflammatory properties, the drug has a higher lipophilic
and hydrophobic profile than other drugs in its class, enabling the drug to be rapidly
absorbed into tissue, with reduced systemic exposure.
The PLA polymer fully degrades into water and carbon dioxide as the drug is released,
ultimately leaving in place a biocompatible stent surface. The polymer is coated onto
the outer (abluminal) side of the stent only, enabling the drug to be released to targeted
tissue. The internally-developed stent used in the BioMatrix system is designed for
increased flexibility in delivery.
®, a biodegradable polymer, and advanced stent design.About Biosensors International Group, Ltd
Biosensors develops, manufactures and markets innovative medical devices used in
interventional cardiology and critical care procedures. Biosensors is well-positioned to
emerge as a leader in drug-eluting stents and has developed a pipeline of nextgeneration
products that are set to gain market share from traditional therapies such as
conventional Drug Eluting Stent, bare-metal stents and open-heart surgery. Biosensors
has internally developed technology to address each components of a drug-eluting stent
system, including a stent, a stent delivery catheter, a biodegradable polymer and a
proprietary anti-restenosis drug. It has three separate drug-eluting stent programs,
BioMatrix
has licensed aspects of its drug-eluting stent technology to four companies.
®, Axxion?, and BioMatrix® Freedom?, a polymer-free drug-eluting stent, andForward Looking Statements
Certain statements herein include forward-looking statements within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements
generally can be identified by the use of forward-looking terminology, such as ?may,?
?will,? ?expect,? ?intend,? ?estimate,? ?anticipate,? ?believe,? ?project? or ?continue? or
the negative thereof or other similar words. All forward-looking statements involve risks
and uncertainties, including, but not limited to, customer acceptance and market share
gains, competition from companies that have greater financial resources; introduction of
new products into the marketplace by competitors; successful product development;
dependence on significant customers; the ability to recruit and retain quality employees
as Biosensors grows; and economic and political conditions globally. Actual results may
differ materially from those discussed in, or implied by, the forward-looking statements.
The forward-looking statements speak only as of the date of this release and Biosensors
assumes no duty to update them to reflect new, changing or unanticipated events or
circumstances.
Dun anyhow let go today. Today alot of people will sell off at discount (to the potiental price) .. If got guts should buy more.
Monday will chiong so high till u get altitude sickness!
| idesa168 Master |
Posted: 18-Jan-2008 09:17 |
 x 0  x 0 |
Double Good News! CE Approval & Trading Halt today in the downturn. If mkt recovers in the afternoon then Halt lifted, we will all laughing to the bank. I am leting go all my holding when starts trading. Mkt sentiment not so good lately. Cheers. |
The original Article
http://www.europcronline.com/fo/exchange/news/detail_news.php?news_id=2331
See website europcronline for the announcement made in the other part of the world. see www.biomatrix.com for the CE mark itself. Okie or not.
idesa.. i differ to your opinion but its your choice. BIG basically is super undervalue.. and even during tis week of consistency bombardment oni affected BIG by mere 0.025 from peak.. I could b totally wrong.. but i intend to let it find its stability first b4 letting go some.. there r good news coming out subsequently.... but i cant determine de time frames of these news..
however.. if u asked me to guess.. haha.. i guessssss oni okie.. Feb.. Mar.. each month one.. haha..
why are we still talking about the announement requesting trading halt when it is already a fact the CE Mark (S/no.0482) is in the bag. ????? See my earlier posting this morning ?
Let talk about how the market will react when trading resumes, let's talk about possibility of NASDAQ dual listing, let's talk about takeover play...
wahlau_eh.. alamak.. though u cant find there.. tis forum aso had attached the link mah... anyway..
attached for you again
|
Jan 17 2008 |
REQUEST FOR TRADING HALT |
| Announcement is submitted with respect to * | BIOSENSORS INT'L GROUP, LTD. |
| Announcement is submitted by * | Loh Chee Mun |
| Designation * | Senior Vice President |
| Date & Time of Broadcast | 17-Jan-2008 17:22:44 |
| Announcement No. | 00037 |
| >> Announcement Details |
| The details of the announcement start here ... |
| Date of Trading Halt * | 18-01-2008 | |
| Time of Trading Halt * | 0900 hours | |
| Reasons for Trading Halt * |
|